On june 6, 2024, the food and drug administration approved imetelstat (rytelo, geron corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk Imetelstat sodium works by blocking the activity of an enzyme called telomerase, which is found at high levels in cells that divide rapidly, including cancer cells. Blocking this enzyme keeps cancer cells …

Imetelstat is fda approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (mds) with transfusion-dependent anemia requiring 4 or more red blood …